The commercial landscape that prompted the study is expanding rapidly. Companies exemplified by TALLY Health in the United States, co-founded by Harvard researcher David Sinclair, offer at-home kits that analyze methylation rates across the genome to produce a biological age estimate. Biological age, in this framework, is a mathematical prediction derived from biomarkers, and the gap between biological and chronological age is presented as a window into how genetics, environment and socioeconomic circumstances shape health. Many firms go further, pairing tests with anti-aging supplements containing compounds such as calcium alpha-ketoglutarate, quercetin, trans-resveratrol, spermidine and fisetin, and encouraging customers to retest repeatedly to track whether their protocols are working. While distinct from true epigenomic editing with tools like CRISPR-dCas9, these strategies similarly aim to reprogram biological processes at the molecular level, blurring the line between science, medicine and commerce.

Methodologically, the study employed a real-time Delphi approach, an iterative survey technique that lets participants see the group’s collective responses and revise their own answers asynchronously. The panel, recruited through purposive sampling from the Francophone research community, included experts in philosophy, chemistry, biology, law, sociology, geriatrics, bioinformatics and genetic discrimination, with professional experience ranging from two to twenty-one years. Of thirty-seven people invited, thirteen began the consultation and ten completed it. They rated thirteen items on a seven-point Likert scale, with a deliberately high consensus threshold of eighty percent, reflecting the ethically sensitive nature of the domain. To interpret the results, the team applied the RULE framework proposed by Matthias Wienroth, which evaluates emerging technologies through three intersecting lenses: Reliability, Utility and LEgitimacy.

On reliability, the panel voiced substantial doubt. No formal consensus was reached on any of the thirteen items, signaling persistent disagreement about the likelihood and severity of emerging problems, but the pattern of responses revealed a general climate of concern. Participants questioned whether current epigenetic tests can deliver on their promises. One panelist argued that treating biological aging as a reversible phenomenon is problematic in itself, given the complexity documented across the epigenetics literature. The study highlights that construct validity remains an active debate: many first-generation epigenetic clocks, including the widely used Horvath and Hannum models, were trained to predict chronological age, not to measure the biological processes of aging. When companies relabel this output as biological age, they may be overstating what the measurement actually captures.

The technical critique extends to measurement stability. Research by Apsley and colleagues found that many DNA methylation probes used in aging algorithms show only average or below-average stability when samples are collected repeatedly within a single five-hour window, with acute stress and early-life adversity further perturbing readings. This instability means that short-term fluctuations in estimated biological age may reflect measurement noise rather than genuine epigenetic change. Consumers who take supplements for a few months and then retest could easily misinterpret such variation as evidence that an intervention is working. The study also notes that second-generation clocks such as PhenoAge and GrimAge, which integrate clinical biomarkers and predict morbidity and mortality, offer stronger construct validity, and some companies have adopted newer models like CheekAge. Yet a 2025 systematic review found no consensus on a standardized method for assessing biological age, underscoring how immature the field remains.

On utility, the panel was split. Four participants were skeptical that knowing one’s biological age offers practical value, three viewed it positively, and three were neutral. Skeptics argued that overall health at a given age is a better indicator and suggested the tests function largely as a way of selling a service. Supporters countered that an unfavorable result might motivate healthier behavior. The discussion also examined whether epigenetic clocks can serve as surrogate endpoints in anti-aging trials, a use that Horvath and Topol caution is not yet validated because changes in epigenetic age have not been shown to reliably predict clinical outcomes. The strongest convergence in the entire consultation, item three, showed eight of ten participants rejecting the scientific justification for marketing supplements alongside epigenetic aging tests, with one panelist calling the practice a potential exploitation of people’s natural anxiety about aging.

Privacy and data governance emerged as critical flashpoints. Epigenetic data can reveal intimate insights, including disease susceptibility and estimated life expectancy, and companies have already expressed interest in using epigenetic age for life insurance underwriting. The information is also being considered for refining DNA phenotyping in forensic investigations, and researchers have warned of potential secondary uses in immigration, employment screening and military contexts. Panelists questioned who would access the data and whether confidentiality assurances could be trusted, echoing long-standing concerns about the direct-to-consumer genetic testing industry. Notably, the item calling for legislation to prevent epigenetic discrimination approached consensus with 79.21 percent stability, the closest any item came to the threshold. Panelists pointed out that existing genetic non-discrimination laws, such as those addressing genetic information in insurance, do not clearly extend to epigenetic data, leaving a regulatory vacuum.

The legitimacy dimension exposed deeper social fault lines. Panelists warned that marketing epigenetic tests as tools of personal empowerment risks shifting responsibility for aging from structural conditions onto individuals. Research by Krieger and colleagues has shown that epigenetic age acceleration is significantly associated with factors such as being born in a Jim Crow state, low parental educational attainment and adult impoverishment, conditions that disproportionately affect Black, Hispanic and socioeconomically marginalized populations. When test results strip away this structural context, accelerated aging caused by racial discrimination and economic injustice gets reframed as a personal deficit with a purchasable solution. Scholars have also warned that epigenetic responsibility narratives disproportionately target mothers and risk reinscribing racialized interpretations of biological difference. Several panelists further argued that the high cost of tests and supplements could worsen health inequities, with one observing that those who can afford repeated testing will demand more follow-up care, effectively privatizing healthcare services.

The consultation also grappled with what the commercialization of epigenetic youth does to collective perceptions of aging. Many participants felt the rhetoric reinforces ageism, pathologizes a natural process, and promotes an individualistic vision of health as capital to be maximized, with one panelist describing the phenomenon as neoliberal biocitizenship and the promise economy. Not all agreed; one participant argued that highlighting the negative aspects of aging is not morally reprehensible and that objecting to longevism is not a valid criticism. This dissent adds nuance, but the majority view held that consumer epigenomics benefits from and contributes to the commodification of longevity while obscuring the social determinants of health. The authors close with six recommendations, including improving public science communication about the limitations of current tests, regulating marketing claims about biological age, strengthening privacy protections, preventing unauthorized secondary uses of epigenetic data, organizing regular scientific guidance on clinical validity, and conducting further research with actual consumers. As epigenetic clocks migrate from laboratories to bathroom counters, the study suggests that the hardest questions are not technical but social: who benefits, who bears the burden, and whether measuring biological age will deepen or distort our understanding of what it means to grow old.

Subject of Research: Ethical, legal and social implications of direct-to-consumer epigenetic biological age testing

Article Title: Consumer epigenomics and biological age editing: ethical, legal, and social implications

Article References: Anvar, S., Dion-Labrie, M., Joly, Y., & Dupras, C. (2026). Consumer epigenomics and biological age editing: ethical, legal, and social implications. Epigenetics Communications, 6(1), Article 3. https://doi.org/10.1186/s43682-026-00044-8

Image Credits: AI Generated

DOI: 10.1186/s43682-026-00044-8

Keywords: epigenetics, biological age, DNA methylation, direct-to-consumer testing, epigenetic clocks, aging, privacy, epigenetic discrimination, health inequities, ageism, supplements, Delphi study